These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. Torizuka T; Tamaki N; Inokuma T; Magata Y; Sasayama S; Yonekura Y; Tanaka A; Yamaoka Y; Yamamoto K; Konishi J J Nucl Med; 1995 Oct; 36(10):1811-7. PubMed ID: 7562048 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT. Kim HO; Kim JS; Shin YM; Ryu JS; Lee YS; Lee SG J Nucl Med; 2010 Dec; 51(12):1849-56. PubMed ID: 21098794 [TBL] [Abstract][Full Text] [Related]
4. Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors. Song JY; Lee YN; Kim YS; Kim SG; Jin SJ; Park JM; Choi GS; Chung JC; Lee MH; Cho YH; Choi MH; Kim DC; Choi HJ; Moon JH; Lee SH; Jeong SW; Jang JY; Kim HS; Kim BS Nucl Med Commun; 2015 Apr; 36(4):319-27. PubMed ID: 25564069 [TBL] [Abstract][Full Text] [Related]
5. 18F-FDG-PET and histopathology in 131I-lipiodol treatment for primary liver cancer. Risse JH; Pauleit D; Bender H; Rabe C; Fischer HP; Biersack HJ; Bucerius J Cancer Biother Radiopharm; 2009 Aug; 24(4):445-52. PubMed ID: 19694579 [TBL] [Abstract][Full Text] [Related]
6. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Shiomi S; Nishiguchi S; Ishizu H; Iwata Y; Sasaki N; Tamori A; Habu D; Takeda T; Kubo S; Ochi H Am J Gastroenterol; 2001 Jun; 96(6):1877-80. PubMed ID: 11419843 [TBL] [Abstract][Full Text] [Related]
7. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Trojan J; Schroeder O; Raedle J; Baum RP; Herrmann G; Jacobi V; Zeuzem S Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736 [TBL] [Abstract][Full Text] [Related]
8. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351 [TBL] [Abstract][Full Text] [Related]
9. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE. Song HJ; Cheng JY; Hu SL; Zhang GY; Fu Y; Zhang YJ Clin Radiol; 2015 Feb; 70(2):128-37. PubMed ID: 25459673 [TBL] [Abstract][Full Text] [Related]
10. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy. Paudyal B; Oriuchi N; Paudyal P; Tsushima Y; Iida Y; Higuchi T; Hanaoka H; Miyakubo M; Takano A; Ishikita T; Endo K Oncol Rep; 2007 Dec; 18(6):1469-73. PubMed ID: 17982632 [TBL] [Abstract][Full Text] [Related]
11. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET. Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429 [TBL] [Abstract][Full Text] [Related]
12. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade. Wolfort RM; Papillion PW; Turnage RH; Lillien DL; Ramaswamy MR; Zibari GB Int Surg; 2010; 95(1):67-75. PubMed ID: 20480845 [TBL] [Abstract][Full Text] [Related]
13. [Malignant tumor with false negative 18F-FDG PET image]. Dong MJ; Lin XT; Zhao J; Guan YH; Zuo CT; Chen X; Dai JZ; Jiang BD Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383 [TBL] [Abstract][Full Text] [Related]
15. [Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma]. Kong YH; Han CJ; Lee SD; Sohn WS; Kim MJ; Ki SS; Kim J; Jeong SH; Kim YC; Lee JO; Cheon GJ; Choi CW; Lim SM Korean J Hepatol; 2004 Dec; 10(4):279-87. PubMed ID: 15613803 [TBL] [Abstract][Full Text] [Related]
16. Clinical value of pre-and postoperative 18F-FDG PET/CT in patients undergoing liver transplantation for hepatocellular carcinoma. Wang XL; Li H; Wang QS; Zhang XL Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1087-91, 1095. PubMed ID: 16939890 [TBL] [Abstract][Full Text] [Related]
17. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. Kim JW; Seong J; Yun M; Lee IJ; Yoon HI; Cho HJ; Han KH Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1172-8. PubMed ID: 21570203 [TBL] [Abstract][Full Text] [Related]
18. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. Yamamoto Y; Nishiyama Y; Kameyama R; Okano K; Kashiwagi H; Deguchi A; Kaji M; Ohkawa M J Nucl Med; 2008 Aug; 49(8):1245-8. PubMed ID: 18632827 [TBL] [Abstract][Full Text] [Related]
19. Value of 18-FDG-positron emission tomography/computed tomography before and after transarterial chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: initial results. Cascales Campos P; Ramirez P; Gonzalez R; Febrero B; Pons JA; Miras M; Sanchez Bueno F; Robles R; Parrilla P Transplant Proc; 2011; 43(6):2213-5. PubMed ID: 21839236 [TBL] [Abstract][Full Text] [Related]
20. [18F-Fluorodeoxyglucose uptake in hepatocellular carcinoma on positron emission tomography correlates with alpha-fetoprotein]. Shang JB; Li YH; Liu FY; Zeng QL; Wang JY; He XF; Chen Y Di Yi Jun Yi Da Xue Xue Bao; 2004 Jun; 24(6):697-9. PubMed ID: 15201094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]